Skin Autofluorescence as a Novel and Noninvasive Technology for Advanced Glycation End Products in Diabetic Foot Ulcers: A Systematic Review and Meta-analysis.

OBJECTIVE: Skin autofluorescence (SAF) has been suggested as a novel and noninvasive technique for assessing tissue accumulation of advanced glycation end products in diabetes and related complications. The aim of this systematic review and meta-analysis was to evaluate the use of SAF in diabetic foot ulcers (DFUs). DATA SOURCES: PubMed/MEDLINE and other digital databases. STUDY SELECTION: The authors included studies comparing the SAF levels in patients with DFU with a non-DFU group to determine its association with DFU risk. DATA EXTRACTION: Collected data included the SAF method and its values in DFU and non-DFU groups, covariates used in adjustment along with the unadjusted and/or multivariate adjusted odds ratios (ORs) for the association of SAF with DFU risk, and other study characteristics. DATA SYNTHESIS: A total of six studies were included in this meta-analysis. Five studies that involved 611 participants were included to compare SAF methods. Compared with the non-DFU group, the DFU group showed a significantly increased level of SAF (standardized mean difference, 0.67; 95% confidence interval [CI], 0.32-1.01; P < .001). The results of meta-analysis of ORs revealed that the increased SAF level was independently associated with increased DFU risk in both unadjusted (OR, 3.16; 95% CI, 2.18-4.57; P < .001) and adjusted models (OR, 3.07; 95% CI, 1.95-4.81; P < .001). CONCLUSIONS: These findings suggest that SAF could be useful as a novel and noninvasive technology to help determine DFU risk. However, further studies establishing its diagnostic and prognostic utilities are needed.

The association of non-invasive skin autofluorescence measurements with cardiovascular and all-cause mortality in hemodialysis patients: a meta-analysis.

BACKGROUND: This systematic review and meta-analysis were aimed to study the association of tissue accumulation of advanced glycation end products (AGEs) measured as skin autofluorescence (SAF) with cardiovascular disease (CVD), cardiovascular mortality (CVM) and all-cause mortality (ACM) in hemodialysis (HD) patients. METHODS: All major databases were searched for relevant studies reporting SAF in dialysis patients. Data for meta-analyses were extracted in the form of odds ratios (OR) and/or hazard ratios (HR) and the pooled overall outcomes were computed for the association of SAF with CVD, CVM, ACM in HD patients using either fixed or random effects meta-analysis based on the between-study heterogeneity. The sensitivity and meta-regression analyses were performed. RESULTS: We included nine studies in this meta-analysis. The SAF levels were associated with higher risk for cardiovascular morbidity (pooled OR = 2.59, Z = 2.30, P = 0.02), cardiovascular (pooled HR = 3.03, Z = 3.13, P = 0.002) and overall mortalities (pooled HR = 2.23, Z = 6.30, P < 0.001) in HD patients. CONCLUSION: In HD patients, the novel and non-invasive measurement of tissue AGEs as SAF levels could be useful for risk estimating the cardiovascular and all-cause mortalities.